MLH1 is altered in 1.38% of malignant solid tumor patients with MLH1 Mutation present in 1.08% of all malignant solid tumor patients [4].

MLH1 Mutation is an inclusion criterion in 15 clinical trials for malignant solid tumor, of which 13 are open and 2 are closed. Of the trials that contain MLH1 Mutation and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [5].

MLH1 is altered in 0.87% of prostate adenocarcinoma patients with MLH1 Mutation present in 0.66% of all prostate adenocarcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain MLH1 Mutation and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [5].

MLH1 is altered in 0.89% of prostate carcinoma patients with MLH1 Mutation present in 0.66% of all prostate carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MLH1 Mutation and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].

MLH1 is altered in 0.88% of ovarian carcinoma patients with MLH1 Mutation present in 0.76% of all ovarian carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MLH1 Mutation and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

MLH1 is altered in 0.86% of breast carcinoma patients with MLH1 Mutation present in 0.62% of all breast carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MLH1 Mutation and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [5].

MLH1 is altered in 3.18% of cervical carcinoma patients with MLH1 Mutation present in 3.18% of all cervical carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MLH1 Mutation and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

MLH1 is altered in 2.29% of colorectal carcinoma patients with MLH1 Mutation present in 1.73% of all colorectal carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MLH1 Mutation and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

MLH1 is altered in 0.84% of non-small cell lung carcinoma patients with MLH1 Mutation present in 0.74% of all non-small cell lung carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 3 clinical trials for non-small cell lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MLH1 Mutation and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

MLH1 is altered in 0.58% of adenocarcinoma of the gastroesophageal junction patients with MLH1 Mutation present in 0.29% of all adenocarcinoma of the gastroesophageal junction patients [4].

MLH1 Mutation is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain MLH1 Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

MLH1 Mutation is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MLH1 Mutation and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

MLH1 is altered in 4.2% of endometrial carcinoma patients with MLH1 Mutation present in 3.18% of all endometrial carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH1 Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MLH1 is altered in 2.12% of bladder carcinoma patients with MLH1 Mutation present in 2.0% of all bladder carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH1 Mutation and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

MLH1 is altered in 2.14% of urothelial carcinoma patients with MLH1 Mutation present in 1.82% of all urothelial carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH1 Mutation and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

MLH1 is altered in 1.91% of melanoma patients with MLH1 Mutation present in 1.72% of all melanoma patients [4].

MLH1 Mutation is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain MLH1 Mutation and melanoma as inclusion criteria, 2 are phase 2 (2 open) [5].

MLH1 is altered in 1.7% of head and neck squamous cell carcinoma patients with MLH1 Mutation present in 1.54% of all head and neck squamous cell carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MLH1 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

MLH1 is altered in 0.97% of non-hodgkin lymphoma patients with MLH1 Mutation present in 0.65% of all non-hodgkin lymphoma patients [4].

MLH1 Mutation is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MLH1 Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

MLH1 is altered in 0.71% of pancreatic carcinoma patients with MLH1 Mutation present in 0.57% of all pancreatic carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH1 Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

MLH1 is altered in 0.67% of soft tissue sarcoma patients with MLH1 Mutation present in 0.54% of all soft tissue sarcoma patients [4].

MLH1 Mutation is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 1 is open and 1 is closed. Of the trials that contain MLH1 Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [5].

MLH1 is altered in 1.67% of fallopian tube carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH1 Mutation and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

MLH1 is altered in 3.85% of penile carcinoma patients with MLH1 Mutation present in 3.85% of all penile carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLH1 Mutation and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MLH1 is altered in 3.34% of malignant uterine neoplasm patients with MLH1 Mutation present in 2.66% of all malignant uterine neoplasm patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

MLH1 is altered in 2.59% of malignant small intestinal neoplasm patients with MLH1 Mutation present in 2.22% of all malignant small intestinal neoplasm patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MLH1 is altered in 2.2% of bladder urothelial carcinoma patients with MLH1 Mutation present in 2.07% of all bladder urothelial carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MLH1 is altered in 2.06% of anal carcinoma patients with MLH1 Mutation present in 2.06% of all anal carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLH1 Mutation and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MLH1 is altered in 2.3% of malignant intestinal neoplasm patients with MLH1 Mutation present in 1.75% of all malignant intestinal neoplasm patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MLH1 is altered in 1.14% of gallbladder carcinoma patients with MLH1 Mutation present in 1.14% of all gallbladder carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MLH1 is altered in 1.59% of gastric adenocarcinoma patients with MLH1 Mutation present in 1.14% of all gastric adenocarcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MLH1 is altered in 1.7% of diffuse large B-cell lymphoma patients with MLH1 Mutation present in 1.13% of all diffuse large B-cell lymphoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MLH1 is altered in 1.58% of gastric carcinoma patients with MLH1 Mutation present in 1.13% of all gastric carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MLH1 is altered in 1.58% of malignant gastric neoplasm patients with MLH1 Mutation present in 1.13% of all malignant gastric neoplasm patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MLH1 is altered in 1.3% of head and neck carcinoma patients with MLH1 Mutation present in 1.11% of all head and neck carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MLH1 is altered in 1.03% of high grade ovarian serous adenocarcinoma patients with MLH1 Mutation present in 0.92% of all high grade ovarian serous adenocarcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLH1 Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MLH1 is altered in 1.41% of malignant esophagogastric neoplasm patients with MLH1 Mutation present in 0.83% of all malignant esophagogastric neoplasm patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MLH1 is altered in 1.76% of small cell lung carcinoma patients with MLH1 Mutation present in 0.78% of all small cell lung carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MLH1 is altered in 0.87% of lung carcinoma patients with MLH1 Mutation present in 0.74% of all lung carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MLH1 is altered in 1.43% of esophageal carcinoma patients with MLH1 Mutation present in 0.72% of all esophageal carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MLH1 is altered in 1.42% of esophageal squamous cell carcinoma patients with MLH1 Mutation present in 0.71% of all esophageal squamous cell carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MLH1 is altered in 0.85% of malignant ovarian epithelial tumor patients with MLH1 Mutation present in 0.71% of all malignant ovarian epithelial tumor patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MLH1 is altered in 0.59% of mature T-cell and NK-cell non-hodgkin lymphoma patients with MLH1 Mutation present in 0.59% of all mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MLH1 is altered in 0.69% of pancreatic adenocarcinoma patients with MLH1 Mutation present in 0.58% of all pancreatic adenocarcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MLH1 is altered in 1.01% of bile duct carcinoma patients with MLH1 Mutation present in 0.5% of all bile duct carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MLH1 is altered in 1.01% of cholangiocarcinoma patients with MLH1 Mutation present in 0.5% of all cholangiocarcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MLH1 is altered in 0.56% of gastrointestinal stromal tumor patients with MLH1 Mutation present in 0.44% of all gastrointestinal stromal tumor patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MLH1 is altered in 0.58% of ampulla of vater carcinoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MLH1 is altered in 0.56% of mantle cell lymphoma patients [4].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 Mutation and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLH1 Mutation and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MLH1 Mutation is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLH1 Mutation and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].